US committee backs terlipressin approval for HRS-1
HRS-1 is an acute and life-threatening syndrome with a survival time of just two weeks if left untreated
Read More
Tag: terlipressin
Terlipressin hits phase III endpoint
CONFIRM is the largest-ever prospective study conducted in patients with hepatorenal syndrome type I.
Read More
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
